Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 7/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 3/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14418705 | 0.93 | GSK3B (0.53) | GSK3BCHEK1CDK2KMT2ASMN1; SMN2 | |
| SCHEMBL13120595 | 0.92 | GSK3B (0.64) | GSK3BCDK2 | |
| SCHEMBL14545839 | 0.91 | GSK3B (0.54) | GSK3BCHEK1CDK2RECQLNAMPT | |
| SCHEMBL14043358 | 0.91 | GSK3B (0.53) | GSK3BCHEK1CDK2KMT2ASMN1; SMN2 | |
| SCHEMBL14418706 | 0.89 | GSK3B (0.52) | GSK3BCHEK1CDK2KMT2ASMN1; SMN2 | |
| SCHEMBL14301574 | 0.87 | GSK3B (0.51) | GSK3BCHEK1CDK2KMT2ASMN1; SMN2 | |
| SCHEMBL14545843 | 0.87 | GSK3B (0.53) | GSK3BCHEK1CDK2KMT2ASMN1; SMN2 | |
| SCHEMBL14418841 | 0.87 | GSK3B (0.53) | GSK3BCHEK1CDK2KMT2ASMN1; SMN2 | |
| SCHEMBL14607248 | 0.87 | GSK3B (0.53) | GSK3BCHEK1CDK2KMT2ASMN1; SMN2 | |
| SCHEMBL14301576 | 0.86 | GSK3B (0.52) | GSK3BCHEK1CDK2KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080050384-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SHERING CORPORATION AND PHARMACOPEIA, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080050384-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | GSK3B 695/4885CHEK1 60/4885CDK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.